Lucentis' Phase III Data Show DME Improvements
By Tom Wall
Friday, March 11, 2011
Genentech reported that data from the first of two pivotal Phase III studies of Lucentis (ranibizumab injection) in diabetic macular edema (DME) showed "rapid and sustained improvement in vision" compared to a placebo injection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.